Business Wire

Save Money While Seeking the Sun: Cost Effective Winter Stays in Egypt

25.1.2023 11:00:00 EET | Business Wire | Press release

Share

Spending the winter season in a warm place has always been popular, whether you’re a digital nomad or a pensioner. But, the rising cost of living over the past year could cause many to reconsider whether, or how, they travel.

While Egypt has long been on travelers’ radar, thanks to its low-cost of living, it has now become a popular long-stay winter destination. In fact, a one month stay in a luxurious three or four-star-hotel can cost less than living in the Western European countries for the same amount of time.

Research collated by the Egyptian Government from a variety of tour operators shows a four-week winter sun stay costs, on average, €1 218 per couple. This includes 160€ per person for a return flight, 25€ per couple for a double room in a four-star hotel and 8€ per person for a three-course dinner at a local restaurant.

In comparison, the average monthly cost of a two-person household for gas, energy, food and beverages is 1 396€ in Italy, 1 509€ in France and 1 601€ in Germany during the winter.

The Egyptian Government is currently promoting and facilitating month long stays at a wide variety of hotels.

Amr El-Kady, CEO of Egyptian Tourism Authority, said: “Egypt is always happy to welcome travelers from Europe. We are doing our best to make the stay as effortless and affordable as possible. This winter season, we invite you to spend the cold months under the kind Egyptian sun, saving the budget and filling life with fantastic new experiences”.

What does Egypt have to offer? Plenty.

From Cairo to Luxor, from the beguiling desert to the lush delta of the Nile, Egypt is a traveler's dream. Whether diving into the rich underwater world of the Red Sea, sailing on the Nile towards the sunset or tracing the secrets of the ancient Egyptians in stunning temple complexes, the land of the pharaohs has something to offer to every visitor.

Among the most famous destinations is the capital Cairo, where you can immerse yourself in all eras of Egyptian history in the Egyptian Museum, and visit the famous Pyramids of Giza with the impressive Sphinx. Another highlight is the city of Luxor, which offers some spectacular wonders, that include the Valley of the Kings, the Temple of Karnak and the legendary Luxor Temple, which is one of the absolute must-sees on any trip and continues to enchant with ancient stories.

If you prefer active and adventurous activities, you don't have to look far. Egypt is not only a diver's paradise, but also offers desert excursions, Nile cruises and breathtaking landscapes such as the Colored Canyon National Park on the Sinai Peninsula. While ecotourism is becoming increasingly popular in the country and even spiritual tours are offered, Egypt is also known for particularly high-quality spa treatments.

A variety of flight connections ensure a pleasant way to get there. There are direct flights to resorts of Egypt from almost every major European city.

Find out what else Egypt has to offer on Egypt travel - Home (experienceegypt.eg)

- ENDS –

Destination images can be downloaded here

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

External Press office
Philipp Koneev, Senior Account Manager, MC Group
p.koneev@mcgroup.com
+49 30 65000‑540

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 19:19:00 EEST | Press release

Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease and lung cancer,” she added. “More broadly, it reinforces the agency’s science-based approach to evaluating products across the co

Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 18:00:00 EEST | Press release

Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border

Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 17:13:00 EEST | Press release

For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and more practical: what it takes to make a specific, high-stakes determination reliable, fast and affordable at scale. A vertical, domain-focused process, gro

Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 17:08:00 EEST | Press release

Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d

Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 17:00:00 EEST | Press release

Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by market capitalization and is home to world-leading companies such as Samsung Electr

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye